Merck to buy cancer drug maker Harpoon Therapeutics for $680m
The acquisition will grant Merck access to Harpoon’s two immunotherapies in early-stage development, one for a type of…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Jan 24
The acquisition will grant Merck access to Harpoon’s two immunotherapies in early-stage development, one for a type of…
09 Jan 24
The deal is expected to grant Novartis access to Cytokinetics' experimental treatment for hypertrophic cardiomyopathy treatment, Aficamten, which…
09 Jan 24
The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate…
08 Jan 24
In the trial, the vaccine demonstrated non-inferiority to Shingrix as measured by humoral immune response along with reduced…
08 Jan 24
The effectiveness of Zelsuvmi was proven in the B-SIMPLE 4 and B-SIMPLE 2 Phase 3 trials in which…
08 Jan 24
Collaboration leverages Tenacia’s expertise in central nervous system drug development and commercialization and will address a significant unmet…
08 Jan 24
GenePHIT, which is now enrolling, will study AB-1002 in adults with NYHA Class III Heart Failure and non-ischemic…
05 Jan 24
Paragon Healthcare, headquartered in Plano, Texas, offers infusion services to patients via its omnichannel model of ambulatory infusion…
05 Jan 24
Funding allows advancement of diverse programs through multiple clinical data readouts, including multiple indications for lead candidate felzartamab
04 Jan 24
The approval was based on the open-label, single-arm Phase 3 BENEGENE-2 study in which a single dose of…